Solara Active Pharma Sciences Limited

SOLARA

INE624Z01016

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:49 2024-04-26 am EDT			5-day change	1st Jan Change
542.4 ^INR	-3.29%		-1.70%	+50.17%

Apr. 08	Solara Active Pharma Sciences Limited Approves Appointment of Mohan Muthunarayanan as an Executive Director	CI
Mar. 26	Solara Active Pharma Gets Board Nod to Sell 100% Stake in SeQuent Penems	MT

Solara Active Pharma Sciences Limited Announces the Resignation of P.V. Raghavendra Rao as Chief Financial Officer

February 14, 2024 at 08:12 am EST

Solara Active Pharma Sciences Limited at its meeting held on February 14, 2024 announced that Mr. P.V. Raghavendra Rao resigned as Chief Financial Officer of the Company from the close of business hours on February 15, 2024, due to personal reasons.

Latest news about Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited Approves Appointment of Mohan Muthunarayanan as an Executive Director	Apr. 08	CI
Solara Active Pharma Gets Board Nod to Sell 100% Stake in SeQuent Penems	Mar. 25	MT
An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited.	Mar. 24	CI
Solara Active Pharma Sciences Appoints CFO	Mar. 08	MT
Solara Active Pharma Sciences Limited Approves Appointment of Arun Kumar Baskaran as Chief Financial Officer	Mar. 08	CI
Solara Active Pharma Sciences' Human Resource Chief Resigns	Feb. 26	MT
Solara Active Pharma HR Chief Steps Down	Feb. 26	MT
Solara Active Pharma Sciences Limited Announces Resignation of Pagadala Srinivasan as Chief Human Resource Officer	Feb. 26	CI
Solara Active Pharma Sciences' CFO Resigns	Feb. 14	MT
Solara Active Pharma Sciences Limited Announces the Resignation of P.V. Raghavendra Rao as Chief Financial Officer	Feb. 14	CI
Transcript : Solara Active Pharma Sciences Limited, Q3 2024 Earnings Call, Feb 14, 2024	Feb. 14
Solara Active Pharma Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Solara Active to Sell Subsidiary's Land	Nov. 14	MT
Solara Active Pharma Sciences Widens Consolidated Loss in Fiscal Q2	Nov. 14	MT
Transcript : Solara Active Pharma Sciences Limited, Q2 2024 Earnings Call, Nov 14, 2023	Nov. 14
Solara Active Pharma Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
Fire Breaks Out at Solara Active Pharma's Puducherry, India Unit	Nov. 05	MT
Solara Active Pharma Names CFO	23-10-19	MT
Solara Active Pharma Sciences Limited Appoints P V Raghavendra Rao as Chief Financial Officer	23-10-19	CI
Solara Active Pharma Sciences Limited Announces Reconstitution of the Committees	23-08-14	CI
Transcript : Solara Active Pharma Sciences Limited, Q1 2024 Earnings Call, Aug 14, 2023	23-08-14
Solara Active Pharma Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Solara Active Pharma's Tamil Nadu Plant in India Clears US FDA Inspection	23-08-06	MT
Solara Active Pharma Sciences Limited Announces Resignation of Directors	23-08-05	CI
Solara Active Pharma Sciences Limited Announces Executive Changes	23-08-01	CI

Chart Solara Active Pharma Sciences Limited

Duration

Period

Chart Solara Active Pharma Sciences Limited

More charts

Company Profile

Solara Active Pharma Sciences Limited is an India-based company offering diversified, commercial active pharmaceutical ingredients (APIs) and contract manufacturing services in over 70 countries. The Company operates through the API segment. Its commercial and research and development products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone HCL (Anxiolytic), Cetirizine Dihydrochloride, Chlorpromazine Hydrochloride, Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Colesevelam Hydrochloride, Cycloserine (Antitubercular), Ethacrynic Acid (Cardiovascular Agent), Hydralazine Hydrochloride (Anti-Hypertensive), Ibuprofen Sodium Dihydrate (Anti-inflammatory), Mesna (Antineoplastic Detoxifying Agent), Mirabegron (OAB Treatment), Pentoxifylline, and others. The Company works with pharmaceutical companies from North America, Europe, and Japan.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Solara Active Pharma Sciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

542.4 INR

Average target price

350 INR

Spread / Average Target

-35.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SOLARA ACTIVE PHARMA SCIENCES LIMITED	+50.17%	234M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals